Live Price Coverage: What’s in Concordia International Corp After Making 52 Week Low?

Live Price Coverage: What's in Concordia International Corp After Making 52 Week Low?

The stock of Concordia International Corp (NASDAQ:CXRX) hit a new 52-week low and has $4.07 target or 12.00% below today’s $4.63 share price. The 9 months bearish chart indicates high risk for the $228.56 million company. The 1-year low was reported on Oct, 3 by If the $4.07 price target is reached, the company will be worth $27.43M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 440,237 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 84.59% since February 29, 2016 and is downtrending. It has underperformed by 96.80% the S&P500.

Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 EPS, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $66.64 million for 0.86 P/E if the $1.35 EPS becomes a reality. After $1.21 actual EPS reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.

Concordia International Corp (NASDAQ:CXRX) Ratings Coverage

Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of Concordia International Corp (NASDAQ:CXRX) has “Buy” rating given on Tuesday, March 29 by Laurentian. The stock of Concordia International Corp (NASDAQ:CXRX) has “Underperformer” rating given on Monday, August 15 by IBC. As per Thursday, August 4, the company rating was downgraded by TD Securities. The firm earned “Speculative Buy” rating on Monday, October 19 by Mackie. The rating was maintained by Scotia Capital with “Sector Outperform” on Friday, October 16. Scotia Capital maintained Concordia International Corp (NASDAQ:CXRX) on Tuesday, September 29 with “Sector Outperform” rating. As per Monday, August 15, the company rating was downgraded by GMP Securities. Canaccord Genuity maintained Concordia International Corp (NASDAQ:CXRX) rating on Tuesday, August 11. Canaccord Genuity has “Buy” rating and $95 price target. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Neutral” rating by Goldman Sachs on Monday, June 6. The rating was maintained by S&P Research on Friday, October 16 with “Buy”.

According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”

More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: which released: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” on September 29, 2016, also with their article: “Concordia International Corp takeover unlikely – Goldman” published on September 27, 2016, published: “STOCK LOSS ALERT: Rosen Law Firm Reminds Concordia International Corp …” on September 26, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: and their article: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX” published on August 17, 2016 as well as‘s news article titled: “Robbins Arroyo LLP: Concordia International Corp. (CXRX) Misled Shareholders …” with publication date: September 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment